Compare SOUN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOUN | ADMA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2021 | 2012 |
| Metric | SOUN | ADMA |
|---|---|---|
| Price | $3.09 | $13.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $12.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 14.7M | 3.8M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $60.18 | $4.83 |
| Revenue Next Year | $43.27 | $14.54 |
| P/E Ratio | ★ N/A | $23.66 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $3.20 | $7.21 |
| 52 Week High | $13.19 | $20.46 |
| Indicator | SOUN | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 17.11 | 64.11 |
| Support Level | N/A | $7.71 |
| Resistance Level | $8.97 | $13.77 |
| Average True Range (ATR) | 0.24 | 0.72 |
| MACD | -0.05 | 0.12 |
| Stochastic Oscillator | 5.36 | 78.53 |
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.